Prediction market trading volume declined in February, with Opinion data shrinking significantly
ChainCatcher news, the total trading volume of prediction markets in February recorded 23.4 billions USD, down about 12% from the record 27.1 billions USD in January, ending five consecutive months of growth and marking the first monthly decline since August 2025. The downturn was mainly dragged by the BNB Chain platform Opinion, whose trading volume plunged from over 10 billions USD to 3.1 billions USD. It is worth noting that the authenticity of Opinion's data has previously been questioned by outsiders.
Meanwhile, platforms showed divergent performances. Kalshi's trading volume rose to a historical high of 9.8 billions USD, further consolidating its industry-leading position; Polymarket saw a slight increase, rising from 7.7 billions USD to 7.9 billions USD.
In recent years, prediction markets have evolved from niche tools to mainstream financial applications, widely used for forecasting events such as elections and economic indicators.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.
TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).
Crypto prices
More
